Tyra Biosciences, Inc. (TYRA)

NASDAQ: TYRA · IEX Real-Time Price · USD
16.39
+0.09 (0.55%)
Mar 28, 2024, 3:59 PM EDT - Market closed

Company Description

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States.

The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.

Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors.

The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma.

The company was incorporated in 2018 and is headquartered in Carlsbad, California.

Tyra Biosciences, Inc.
Tyra Biosciences logo
Country United States
Founded 2018
IPO Date Sep 15, 2021
Industry Biotechnology
Sector Healthcare
Employees 49
CEO Dr. Todd Harris Ph.D.

Contact Details

Address:
2656 State Street
Carlsbad, California 92008
United States
Phone (619) 728-4760
Website tyra.bio

Stock Details

Ticker Symbol TYRA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $16.00
CIK Code 0001863127
CUSIP Number 90240B106
ISIN Number US90240B1061
Employer ID 83-1476348
SIC Code 2834

Key Executives

Name Position
Dr. Todd Harris Ph.D. Co-Founder, President, Chief Executive Officer, Secretary, Treasurer and Director
Daniel Bensen Co-Founder and Chief Operating Officer
Ali D. Fawaz J.D. General Counsel and Secretary
Alan Fuhrman Chief Financial Officer
Dr. Robert L. Hudkins Ph.D. Chief Technology Officer
Dr. Ronald V. Swanson Ph.D. Chief Scientific Officer
Sarah Honig Vice President of Corporate Development and Strategy
Dr. Hiroomi Tada M.D., Ph.D. Chief Medical Officer
Dr. Piyush R. Patel Ph.D. Chief Development Officer
Amy Conrad Investor Contact

Latest SEC Filings

Date Type Title
Mar 19, 2024 S-8 Securities to be offered to employees in employee benefit plans
Mar 19, 2024 S-3 Registration statement under Securities Act of 1933
Mar 19, 2024 10-K Annual Report
Mar 19, 2024 8-K Current Report
Mar 11, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 13, 2024 D Notice of Exempt Offering of Securities
Feb 12, 2024 144 Filing
Feb 9, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 8, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership